No Data
Tryptamine to Plug $6M Placement Funding Into Acceleration of IV-infused Psilocybin Treatment Trials
Tryptamine Therapeutics A$6 Million Placement Cornerstoned by Merchant Biotech Fund and Dr Daniel Tillett | ASX:TYP, OTC:TYPTF
Just the Facts: Tryptamine Therapeutics' TRP-8803 Clears Phase 1b Safety Trial | ASX:TYP, OTC:TYPTF
Tryptamine Therapeutics Psilocybin Asset TRP-8803 Clears Safety Test Following Phase 1b Trial
Tryptamine Therapeutics Ltd: Annual Report to shareholders
Tryptamine Therapeutics Ltd: Preliminary Final Report Reporting Adjustments
No Data
No Data